UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
FORM 8-K
_______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 14, 2011
_______________
HELIX BIOMEDIX, INC.
(Exact name of registrant as specified in its charter)
_______________
| DELAWARE | 033-20897-D | 91-2099117 |
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.) |
22118 20th Avenue S.E., Suite 204
Bothell, Washington 98021
(425) 402-8400
(Address and telephone number of registrant’s principal executive offices)
_______________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 1.01 | Entry into a Material Definitive Agreement. |
On December 14, 2011, the Company entered into a Third Amendment to First Amended and Restated License Agreement (the “Third Amendment”) with Grant Industries, Inc., which amends the First Amended and Restated License Agreement between the parties dated September 12, 2007 as amended effective as of December 10, 2008 and May 6, 2010 (the “Agreement”). The Third Amendment (i) removes one of the Company’s proprietary peptides from the scope of the license granted pursuant to the Agreement, (ii) requires that the peptides subject to such license be purchased from the Company, (iii) extends the term of the Agreement until December 31, 2014 and (iv) establishes minimum royalty obligations for 2012, 2013 and 2014.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HELIX BIOMEDIX, INC. | |||
| Dated: December 16, 2011 | By: | /s/ R. Stephen Beatty | |
| R. Stephen Beatty | |||
| President and Chief Executive Officer |